Shilpa Medicare liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

11.68×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.31×	1.31×	1.46×	1.26×	0.98×
0.88×	0.88×	0.95×	0.77×	0.57×
41.3	41.3	26.0	30.2	21.3
262	262	311	183	−14.9

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SHILPAMED₹935.60

Shilpa Medicare Ltd.

· Pharma & Health

₹ CrorePeersNATCOPHARM SPARC STAR RUBICON SUPRIYA THYROCARE VIYASH PARKHOSPSMcap ₹18,300 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	11.68
Current Ratio	0.98	1.26	1.46	1.31	1.31
Quick Ratio	0.57	0.77	0.95	0.88	0.88
Cash, Equiv & ST Investments	21.3	30.2	26.0	41.3	41.3
Working Capital	-14.9	183.5	311.4	261.7	261.7

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.